New Bioabsorbable Septal Repair Implant for Percutaneous Closure of a Patent Foramen Ovale: Short-Term Results of a Single-Centre Experience

被引:10
作者
Van den Branden, B. J. L. [1 ]
Post, M. C. [1 ]
Jaarsma, W. [1 ]
ten Berg, J. M. [1 ]
Suttorp, M. J. [1 ]
机构
[1] St Antonius Hosp, Dept Cardiol, NL-3435 CM Nieuwegein, Netherlands
关键词
congenital heart defect; catheterization; efficacy; TRANSCATHETER CLOSURE; PARADOXICAL EMBOLISM; FOLLOW-UP; DEVICE; OCCLUDER; AMPLATZER; EVENTS; STROKE; RISK; COMPLICATIONS;
D O I
10.1002/ccd.21998
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Permanent implants for closure of a patent foramen ovale (PFO) have a number of possible disadvantages including erosions, thrombus formation, and allergic reactions. The incidence of adverse events may be lower using a bioabsorbable device. Objective: To evaluate the short-term safety and efficacy of a new bioabsorbable closure device. Methods: All 35 consecutive patients (21 female, mean age 47.9 +/- 10.8 years), who underwent a percutaneous PFO closure between November 2007 and July 2008, were included. All complications were reported. The efficacy was based on the residual shunting the day after implant and at 1 month follow-up and was graded as minimal, moderate, or severe, using contrast transthoracic echocardiography with the Valsalva manoeuvre. Results: The only in-hospital complication was a surgical device retrieval from the femoral vein. Four patients developed a minimal inguinal haematoma. One day after closure, residual shunting was present in 56% of the patients (minimal 27%, moderate 23% and severe 6%). At I month follow-up (n = 33), one patient developed a transient neurological deficit and three patients suffered from paroxysmal atrial fibrillation. A residual shunt at 1 month was present in 45% of the patients (minimal 30%, moderate 12%, and severe 3%). Conclusions: Percutaneous PFO closure using the bioabsorbable closure device seems to be safe. However, a high rate of residual shunting is present at 1 month follow-up. Long-term follow-up data are necessary to evaluate the efficacy and safety of this device. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:286 / 290
页数:5
相关论文
共 44 条
  • [41] Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: real-world experience from a single-centre retrospective cohort in Taiwan
    Huang, Yi-Chia
    Sun, Hsin-Yun
    Chuang, Yu-Chung
    Huang, Yu-Shan
    Lin, Kuan-Yin
    Huang, Sung-Hsi
    Chen, Guan-Jhou
    Luo, Yu-Zheng
    Wu, Pei-Ying
    Liu, Wen-Chun
    Hung, Chien-Ching
    Chang, Shan-Chwen
    BMJ OPEN, 2019, 9 (09):
  • [42] MitraClip therapy and surgical edge-to-edge repair in patients with severe left ventricular dysfunction and secondary mitral regurgitation: mid-term results of a single-centre experience
    De Bonis, Michele
    Taramasso, Maurizio
    Lapenna, Elisabetta
    Denti, Paolo
    La Canna, Giovanni
    Buzzatti, Nicola
    Pappalardo, Federico
    Di Giannuario, Giovanna
    Cioni, Micaela
    Giacomini, Andrea
    Alfieri, Ottavio
    Oei, F.
    Kirsch, M.
    Treede, H.
    Obadia, J. -F.
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 49 (01) : 255 - 262
  • [43] A single-centre cohort and short-term follow-up of patients who developed persistent new onset left bundle branch block after transcatheter aortic valve replacement
    Akdemir, Baris
    Roukoz, Henri
    ACTA CARDIOLOGICA, 2020, 75 (04) : 360 - 365
  • [44] Skin antisepsis with chlorhexidine-alcohol versus povidone iodine- alcohol, combined or not with use of a bundle of new devices, for prevention of short-term peripheral venous catheter-related infectious complications and catheter failure: an open-label, single-centre, randomised, four-parallel group, two-by-two factorial trial: CLEAN 3 protocol study
    Guenezan, Jeremy
    Drugeon, Bertrand
    O'Neill, Roderick
    Caillaud, Diane
    Senamaud, Clement
    Pouzet, Catherine
    Seguin, Sabrina
    Frasca, Denis
    Mimoz, Olivier
    BMJ OPEN, 2019, 9 (04):